指南与共识心血管技术与安全

欧洲心脏病学会癌症治疗相关心血管毒性预防与管理质量指标

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.
指南 / 共识 · Eur Heart J Qual Care Clin Outcomes · 2022-01-01

该文件遵循欧洲心脏病学会质量指标制定方法,通过识别关键照护域、系统文献综述和改良德尔菲法,制定了5项主要和9项次要质量指标,覆盖结构框架、基线心血管风险评估、癌症治疗相关心血管毒性、结局预测因素及癌症治疗期间心血管并发症监测五个领域,旨在量化并改善指南推荐临床实践的依从性和患者结局。

要点

  • 质量指标覆盖结构框架、基线风险评估、心血管毒性、结局预测因素和监测五个照护域。
  • 共制定5项主要和9项次要质量指标,采用改良德尔菲法筛选。
  • 指标旨在量化并改善对指南推荐临床实践的依从性及患者结局。

核心结论

  • 文件呈现了欧洲心脏病学会癌症心脏病学质量指标及其制定过程和筛选的科学依据概述,这些指标旨在量化并改善对指南推荐临床实践的依从性并改善患者结局。

研究设计与样本

  • 遵循欧洲心脏病学会质量指标制定方法,包括识别关键照护域、系统文献综述形成候选指标、改良德尔菲法筛选最终指标,与2022年欧洲心脏病学会癌症心脏病学指南撰写并行并与欧洲血液学协会、欧洲放射肿瘤治疗学会和国际癌症心脏病学会合作完成。

诊断标准与关键数值

  • 共选择5项主要和9项次要质量指标,覆盖五个照护域:结构框架、基线心血管风险评估、癌症治疗相关心血管毒性、结局预测因素、癌症治疗期间心血管并发症监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity.

METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.

CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

来源:Eur Heart J Qual Care Clin Outcomes,查看原文。版权归原作者所有。

引用

  1. Lee GA, Aktaa S, Baker E, et al. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes. 2022. PMID: 36316010. doi:10.1093/ehjqcco/qcac070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。